{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:31:15Z","timestamp":1790544675137,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jcv.2020.104380","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T01:45:32Z","timestamp":1587519932000},"page":"104380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"special_numbering":"C","title":["Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-5618","authenticated-orcid":false,"given":"Saeed K.","family":"Alzghari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie S.","family":"Acu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2020.104380_bib0005","unstructured":"Maps & Trends. Johns Hopkins Coronavirus Resource Center. https:\/\/coronavirus.jhu.edu\/data. (Accessed April 13, 2020)."},{"key":"10.1016\/j.jcv.2020.104380_bib0010","article-title":"Potential therapeutic agents against COVID-19: what we know so far","author":"Lu","year":"2020","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jcv.2020.104380_bib0015","doi-asserted-by":"crossref","DOI":"10.1007\/s00011-020-01342-0","article-title":"The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients","author":"Yuan","year":"2020","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jcv.2020.104380_bib0020","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jcv.2020.104380_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"issue":"00026","key":"10.1016\/j.jcv.2020.104380_bib0030","first-page":"v1","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"202003","author":"Xu","year":"2020","journal-title":"ChinaXiv"},{"key":"10.1016\/j.jcv.2020.104380_bib0035","first-page":"1","article-title":"A case of novel coronavirus disease 19 in a chronic hemodialysis patient presenting with gastroenteritis and developing severe pulmonary disease","author":"Ferrey","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jcv.2020.104380_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report","author":"Michot","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jcv.2020.104380_bib0045","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2020-217442","article-title":"COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD","volume":"79","author":"Mihai","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jcv.2020.104380_bib0050","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcv.2020.104380_bib0055","series-title":"Actemra [Package Insert]","year":"2017"},{"issue":"1","key":"10.1016\/j.jcv.2020.104380_bib0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.jcv.2020.104380_bib0065","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcv.2020.104380_bib0070","article-title":"Clinical features of 69 cases with Coronavirus Disease 2019 in Wuhan, China","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2020.104380_bib0075","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics","author":"Cantini","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jcv.2020.104380_bib0080","series-title":"Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection","author":"Bhimraj","year":"2011"},{"key":"10.1016\/j.jcv.2020.104380_bib0085","series-title":"American Thoracic Society","article-title":"Interim Guidance on Management Pending Empirical Evidence","author":"Wilson","year":"2020"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220301220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220301220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:12:14Z","timestamp":1761361934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653220301220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":17,"alternative-id":["S1386653220301220"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104380","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104380"}}